Organization
Amgen, Thousand Oaks, United States of America
2 abstracts
Abstract
A FIRST IN CLASS THERAPEUTIC NANOPARTICLE FOR SPECIFIC TARGETING OF ANTI-CITRULLINATED PROTEIN ANTIBODY AMELIORATES SERUM TRANSFER AND COLLAGEN INDUCED ARTHRITISOrg: Danish Technical University, Copenhagen, Denmark, Aarhus University, Aarhus, Denmark, Aarhus University Hospital, Aarhus, Denmark, Amgen, Thousand Oaks, United States of America, Stanford University, Stanford, United States of America,
Abstract
ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY Org: Metroplex Clinical Research Center, Dallas, United States, Instituto de Investigaciόn Hospital, Madrid, Spain, Amgen, Thousand Oaks, United States of America, Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany, Altoona Center for Clinical Research, Duncansville, United States,